Lenvatinib Mesylate CAS 857890-39-2 Su'ega 98.0~102.0% Falegaosimea

Fa'amatalaga Puupuu:

Igoa vaila'au: Lenvatinib Mesylate

CAS: 857890-39-2

Su'ega: 98.0~102.0%

Fa'aaliga: Pa'epa'e ile Pa'epa'e Pa'epa'e po'o tioata

Fa'afeso'ota'i: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Fa'amatalaga Oloa

Oloa Fa'atatau

Faailoga o oloa

Fa'amatalaga:

Meatotino tau vailaau:

Igoa Vailaau Lenvatinib Mesylate
Synonyms 4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-Methoxy-6-Quinolinecarboxamide Mesylate;E 7080 Mesylate;Lenvima
Numera CAS 857890-39-2
CAT Numera RF-PI1975
Tulaga Fa'asoa I Fa'atauga, Oloa Fua e O'o i Tone
Fuafua mole C21H19N4O4Cl.CH4O3S
Molecular Weight 522.96
Fa'ailoga Ruifu Chemical

Fa'amatalaga:

Aitema Fa'amatalaga
Fa'aaliga Pa'epa'e i le Pa'epa'e Pa'epa'e po'o tioata
Fa'ailoaga Saunia e IR;E ala i le UV;Saunia e HPLC
Solubility E Suavai Teisi i le Vai, E le mafai ona solu ile Ethanol
Lisi Lisi 228.0~230.0 ℃
Suavai (KF) <1.00%
Toega i luga o le mumu <0.10%
Metala mamafa <20ppm
Mea Fa'atatau
So'o se Fa'aleaga Ta'itasi <0.50%
Aofa'i Fa'aleaga <1.00%
Su'ega / Su'esu'ega Metotia 98.0~102.0% (Fa'avae HPLC ile Fa'amago)
To'atele Tele 0.40gm/ml~0.60gm/ml
Tulaga Su'ega Pisinisi Tulaga
Fa'aoga API

Paket & Teuina:

afifi: Fagu, ato pepa alumini, 25kg/Kati Pusa, pe tusa ai ma manaoga o tagata faatau

Tulaga teuina:Teu i totonu o pusa faʻamaufaʻailoga i se nofoaga malulu ma mago;Puipui mai le malamalama ma le susu

Tulaga lelei:

1

FAQ:

Talosaga:

Lenvatinib Mesylate (CAS: 857890-39-2) o se faʻaoga tautala ma le tele-faʻaogaina o le inhibitor VEGFR1-3, FGFR1-4, PDGFR, KIT, ma RET, faʻatasi ai ma gaioiga faʻamalosi malosi.O le Lenvatinib Mesylate o se fa'atosina o le tyrosine kinase (RTK) e iai le filifiliga mo le VEGFR2.O lo'o fa'aalia ai le gaioiga antineoplastic, ma ua fa'ailoa mai mo le togafitia o tagata mama'i i le fa'alotoifale faifaipea po'o metastatic, alualu i luma, radioactive iodine (RAI) -refractory differentiated thyroid cancer.Lenvatinib Mesylate na faʻamaonia muamua e le US Food and Drug Administration (FDA) ia Feb 13, 2015, ona faʻamaonia lea e Pharmaceuticals and Medical Devices Agency of Japan (PMDA) i le Mati 26, 2015, ma faʻamaonia e le European Medicine Agency (EMA) i luga. Me 28, 2015. Na atiina ae ma maketiina o Lenvima® e Eisai.O le Lenvatinib Mesylate o se fa'amalosaga tele o le tyrosine kinase o lo'o fa'aogaina fa'atasi ma se faiga fa'amaufa'ailoga fa'apitoa e fa'alavelaveina ai gaioiga kinase o le fa'atupuina o le endothelial vascular (VEGF), fa'aopoopo i isi kinases tyrosine e feso'ota'i proangiogenic ma oncogenic e manatu e a'afia i le fa'atuputeleina o le tuma. .O lo'o fa'ailoa mai mo le togafitiga o le fa'asolosolo fa'asolosolo o le radioiodine-refractory differentiated thyroid cancer.Lenvimao lo'o fa'aaogaina e ia lava e togafitia ai le kanesa o thyroid eseese (DTC), o se ituaiga o kanesa o lauroid e le toe mafai ona togafitia i le iodine radioactive ma o lo'o aga'i i luma.LENVIMA e fa'aoga fa'atasi ma se isi vaila'au e ta'ua o le everolimus e togafitia ai tagata matutua o lo'o maua i se ituaiga o kanesa fatuga'o e ta'ua o le advanced renal cell carcinoma (RCC) pe a mae'a le tasi togafitiga ma se isi vaila'au e puipuia ai le kanesa.

Tusi lau savali iinei ma lafo mai ia i matou